Catalysts / CADL
Upcoming FDA decisions and readouts we track for Candel Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Candel Therapeutics (CADL, listed on Nasdaq). They cover 2 programmes: Linoserpaturev (CAN-2409) (Recurrent high-grade glioma) and Aglatimagene besadenovec (CAN-2409) (Localised prostate cancer).
First on the list: the Phase 1B readout for Linoserpaturev (CAN-2409) (Recurrent high-grade glioma), guided by the company to Q4 2026. By stage, the upcoming rows are 1 Phase 1B readout and 1 Regulatory submission.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; NDA vs BLA: the two kinds of US drug application.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Candel Therapeutics CADL · Nasdaq | Linoserpaturev (CAN-2409) | Recurrent high-grade glioma | Q4 2026 company guidance |
Phase 1B readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Candel Therapeutics CADL · Nasdaq | Aglatimagene besadenovec (CAN-2409) | Localised prostate cancer | Q4 2026 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList